Advanced Biologics Adds More Patient Results Showcasing Osteoamp&#0174'S Superior Fusion Rates Compared to Rhbmp-2

Published: Apr 29, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LADERA RANCH, Calif., April 29, 2013 /PRNewswire/ -- Advanced Biologics announced today that they will be presenting expanded data at the American Academy of Neurosurgeons (AANS) meeting this week in New Orleans, LA showcasing a clinical study demonstrating superior lumbar fusion rates for OsteoAMP® when compared to rhBMP-2 (Infuse®, Medtronic). In a blinded, multi-center clinical and radiological study, fusion analysis showed superiority for OsteoAMP® in producing fusions when compared to rhBMP-2. Fusions (TLIF/LLIF) were assessed by a blinded independent radiologist at various time points (3months, 6months, 12months and 18 months) for both OsteoAMP and rhBMP-2. Analysis showed statistically significant superiority for OsteoAMP at all time points (p<0.02). In addition, the study revealed that patients in the rhBMP-2 had >80% the rate of radiologically-evident adverse events than OsteoAMP. The study now represents 247 patients and has been submitted for further peer review.

"OsteoAMP® remains to be the only orthobiologic on the market with pivotal head-to-head clinical data showing superiority achieving fusion against Medtronic's Infuse®," stated President, Amit Govil. "The clinical data further substantiates OsteoAMP as a viable option for surgeons, hospitals and patients searching for a more cost-effective and safer option to rhBMP-2. We are currently enrolling patients in additional clinical trials to further validate our technology."

OsteoAMP® is an award-winning allogeneic growth factor that is a lower-cost alternative to recombinant growth factors, such as rhBMP-2 (Infuse®, Medtronic). Additionally, OsteoAMP®'s four distinctive formats (granules, compressible sponges, putty, and structural grafts) provide a distinct advantage by allowing surgeons to tailor deliver the technology according to their needs in surgery.

About Advanced Biologics

Founded in 2009, Advanced Biologics (ABC) is a privately-held company focused on developing innovative and clinically relevant biologic solutions across a wide degree of medical specialties. The OsteoAMP® family of osteoinductive/conductive products is the first line of orthobiologic offerings produced by ABC. ABC has been recognized three times as 'Best New Technology' during the Orthopedics This Week Spine Technology Awards.

Scott Cadotte

SOURCE Advanced Biologics, LLC

Help employers find you! Check out all the jobs and post your resume.

Back to news